The notices it replaced
Its page was not saved, so the notices it replaced are not known.
Who won it before
2 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $2,447,470 in first-year total cost, median $1,223,735.
Most frequent study sections
- Special Emphasis Panel[ZDA1 IXN-O (06)]1
- Special Emphasis Panel[ZDA1 IXN-O (11)]1
Most frequent institutions
- TEMPLE UNIV OF THE COMMONWEALTH1
- US WORLDMEDS, LLC1
| FY | Project | PIs | Institution | First-year cost | Study section |
|---|---|---|---|---|---|
| 2020 | Drug development of clavulanic acid, a GLT-1 activator: proof of concept for cocaine use disorder1U01DA048517-01A1 | MORRISON, MARY F. | TEMPLE UNIV OF THE COMMONWEALTH, PA | $1,777,470 | ZDA1 |
| 2018 | Accelerated Development of Lofexidine for Neonatal Opioid Withdrawal Syndrome1R01DA047690-01 | GULLO, KRISTEN LEANN | US WORLDMEDS, LLC, KY | $670,000 | ZDA1 |
Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.